
    
      You will receive CRLX101 and bevacizumab through an intravenous (IV) infusion once every 14
      days. Each cycle is 28 days. You will continue to receive both drugs until you and/or the
      research doctor decides it may not be in your best interest to continue.

      You will receive premedication including decadron, zantac and benadryl to help prevent an
      allergic reaction and nausea prior to your CRLX101 infusion.You will also receive IV fluid
      before and after the study drug administration to keep you hydrated. It will be important for
      you to drink water regularly in between study visits.You will be treated as an outpatient. At
      every clinic visit, you will undergo the following assessments: Medical history, physical
      examination, vital signs, performance status, routine blood tests, urine tests, assessment
      for any new side effects, CT evaluation (every 8 weeks).

      You will have an end of study visit within 30 days of your last dose.
    
  